Reversal of hyperlipidemia and lipodystrophy in patients switching therapy to nelfinavir.
Duncombe
C
C
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006678:HIV / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000517:prevention & control*; D008060:Lipodystrophy / Q000517:prevention & control*; D019888:Nelfinavir / Q000627:therapeutic use*; D011446:Prospective Studies
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D019888:Nelfinavir